0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 03:02 ET (08:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.